Abstracts Archive - Page 320 of 1683 - ATC Abstracts

2021 American Transplant Congress
Has the Proportional Rise in Deceased Organ Donation Rate Over Last 5 Years Been Optimal? Data-based, Forecasting Model Analysis of UNOS/NHSBT UK Donor Data
H. Sharma¹, A. Sharma²
¹Transplant and Vascular Access Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom, ²Data Analytics, Loyola University, Chicago, IL
*Purpose: The increase in deceased donor numbers since last decade has been widely reported. We aim to analyse if the trend in rise of numbers…
2021 American Transplant Congress
Patient Perspective of the Implementation of Virtual Medicine in a Post-kidney Transplant Clinic
S. Mann¹, M. Kadatz¹, J. Lan¹, O. Johnston¹, C. Luo²
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada
*Purpose: COVID-19 dramatically altered the model of health care delivery for transplant recipients, necessitating the routine use of virtual medicine. This resulted in consequences for…
2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
2021 American Transplant Congress
Risk Factors Predicting Outcomes in Long-Term Pediatric Kidney Transplant Graft Survival
A. Anand, T. H. Malik, J. Dunson, M. F. McDonald, C. R. Christmann, N. Nguyen Galvan, C. O'Mahony, J. A. Goss, P. R. Srivaths, E. D. Brewer, A. Rana
Baylor College of Medicine, Houston, TX
*Purpose: Pediatric kidney transplant recipients generally have good outcomes post-transplantation; however, the younger age and longer lifespan after transplantation in the pediatric population make understanding…
2021 American Transplant Congress
High Degree of Center Variation in Simultaneous Heart Kidney Transplant: Opportunities for Standardization
B. I. Shaw¹, M. L. Samoylova¹, S. J. Kesseli¹, D. Olaso², A. S. Barbas¹, D. L. Sudan¹, L. E. Boulware³, L. M. McElroy¹
¹Surgery, Duke University, Durham, NC, ²School of Medicine, Duke University, Durham, NC, ³Medicine-Nephrology, Duke University, Durham, NC
*Purpose: Simultaneous heart kidney transplant (SHK) is increasingly common and unregulated. We sought to understand variation in patient selection for SHK at the center level.*Methods:…
2021 American Transplant Congress
Profile of SARS-CoV-2 Antibodies in Patients Awaiting Kidney Transplantation
L. Muir¹, A. Jaffer², C. Rees-Spear¹, V. Gopalan², F. Chang², G. Vaitkute¹, R. Fernando³, C. Roustan⁴, A. Rosa⁴, C. Earl⁴, A. Salama², P. Cherepanov⁴, L. E. McCoy¹, R. Motallebzadeh²
¹Institute of Immunity & Transplantation, University College London, London, United Kingdom, ²Nephrology & Transplantation, Royal Free London Hospital NHS Trust, London, United Kingdom, ³Anthony Nolan Institute, Royal Free London Hospital NHS Trust, London, United Kingdom, ⁴The Francis Crick Institute, London, United Kingdom
*Purpose: Patients with end-stage kidney disease (ESKD) represent an extremely vulnerable group with many risk factors for adverse outcomes following SARS-CoV-2 infection. Key questions pertaining…
2021 American Transplant Congress
Outcomes of Cytomegalovirus Status Determining Induction Therapy in Lung Transplant
K. Heagler¹, J. Lyons¹, B. Bemiss², P. Stracener¹
¹Pharmacy, Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: At the study institution, basiliximab induction is withheld in lung transplant recipients who are cytomegalovirus (CMV) high risk due to concern for increased CMV…
2021 American Transplant Congress
Growth Differentiation Factor 15 Predictor Value is Superior to Troponin I in the Evaluation of Kidney Transplant Candidates
M. de Cos Gomez¹, M. Garcia Unzueta², A. Benito Hernandez¹, J. Mazon Ruiz¹, M. Perez Arnedo¹, A. Aguilera Fernandez¹, R. Valero San Cecilio¹, J. Ruiz San Millan¹, E. Rodrigo Calabia¹
¹Nephrology, Marques de Valdecilla University Hospital - IDIVAL, Santander, Spain, ²Clinical Analysis, Marques de Valdecilla University Hospital - IDIVAL, Santander, Spain
*Purpose: Pretransplant cardiac troponin I (cTNI) has demonstrated its predictor value of survival after kidney transplant in previous studies. Growth differentiation factor 15 (GDF-15) is…
2021 American Transplant Congress
Outcomes of Liver Transplantation for Combined Hepatocellular Cholangiocarcinoma: A Single-center Experience
Y. Liu¹, C. Hanlon¹, S. Zhou¹, D. Toy¹, K. King², K. Zhou³, J. Kahn³, L. Yuan³
¹Internal Medicine, USC Keck School of Medicine, Los Angeles, CA, ²Radiology, USC Keck School of Medicine, Los Angeles, CA, ³Internal Medicine - Gastrointestinal and Liver Disease, USC Keck School of Medicine, Los Angeles, CA
*Purpose: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a hepatic tumor that exhibits histological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). cHCC-CCA is often diagnosed…
2021 American Transplant Congress
Perioperative Blood Transfusion is Associated with the Development of New HLA Antibodies After Adult Lung Transplantation
A. Hicks¹, A. Stoker², M. Cooter², A. Ali³, J. Klapper⁴, J. Poisson⁵, D. Chen⁵, J. Haney⁴, K. Ghadimi², M. Hartwig⁴, I. Welsby², B. Bottiger²
¹Anesthesiology, Duke University Hospital, South Portland, ME, ²Anesthesiology, Duke University Hospital, Durham, NC, ³Pulmonology, Allergy and Critical Care Medicine, Duke University Hospital, Durham, NC, ⁴Cardiothoracic Surgery, Duke University Hospital, Durham, NC, ⁵Pathology, Duke University Hospital, Durham, NC
*Purpose: Lung transplant (LT) recipients who develop new antibodies to human leukocyte antigen (HLA) have associated with chronic lung allograft dysfunction and worsened outcomes. We…